### Scientific Program

**Sunday 7 December, 2014**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
<th>Chair</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30–19:00</td>
<td>Registration desk open</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00–13:00</td>
<td><strong>ASCEPT Council Meeting</strong></td>
<td>Room: Clarendon Room C, Level 2</td>
<td>Prof Andrew Somogyi</td>
<td>Dr Katie Leach, Monash University&lt;br&gt;Prof Patrick Kwan, Royal Melbourne Hospital&lt;br&gt;Assoc Prof Les Sheffield, GenesFX Health</td>
</tr>
<tr>
<td></td>
<td><strong>PGx Workshop (10:00 - 12:00)</strong></td>
<td>Room: Clarendon Room D, Level 2</td>
<td>Asst Prof Andrew Kruse, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Lipidic Cubic Phase (LCP) Workshop</strong></td>
<td>Room: Clarendon Room E, Level 2</td>
<td>Support by GenesWorks</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Student/ECR short presentations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pharmacogenomics SIG AGM</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00–16:00</td>
<td><strong>Clinical Pharmacology Workshop</strong></td>
<td>Room: Clarendon Room C, Level 2</td>
<td>Dr Ingrid Hopper</td>
<td>Dr Tilenka Thynne, Flinders Medical Centre&lt;br&gt;Assoc Prof Matt Doogue, Otago University, New Zealand&lt;br&gt;Dr Joel Iedema, Redland Hospital</td>
</tr>
<tr>
<td></td>
<td><strong>Careers Workshop</strong></td>
<td>Room: Clarendon Room D, Level 2</td>
<td>Dr Nicole Jones</td>
<td>Dr Jane Bourke, Monash University&lt;br&gt;Dr Tamara Paravincini, The University of Queensland; RAMIT&lt;br&gt;Dr Justin Hamilton, Australian Centre for Blood Diseases&lt;br&gt;Dr Michelle Halls, Monash University</td>
</tr>
<tr>
<td></td>
<td><strong>Education Workshop</strong></td>
<td>Room: Clarendon Room E, Level 2</td>
<td>Dr Anna-Marie Babey</td>
<td>Cindy O’Walley, RMIT University&lt;br&gt;Dr David Foster, University of South Australia</td>
</tr>
<tr>
<td>16:30–17:30</td>
<td><strong>Opening session and plenary presentation</strong></td>
<td>Room: Clarendon Auditorium, Level 2</td>
<td>Assoc Prof Peter Molenaar</td>
<td>Prof Daniel Heyer, The University of Melbourne</td>
</tr>
<tr>
<td></td>
<td><strong>Therapeutic agents and drug targets: GPCRs and beyond, opportunities and challenges - 101</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30–19:00</td>
<td><strong>Welcome Reception</strong></td>
<td>Clarendon Auditorium foyer, Level 2, Melbourne Convention and Exhibition Centre</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Monday 8 December, 2014

#### 07:00–18:00
**Registration desk open**

#### 08:30–09:30
**Plenary presentation: British Pharmacological Society visitor**

**Room:** Clarendon Auditorium, Level 2

**Chair:** Assoc Prof Peter Molenaar

*Translating G-protein coupled receptors from chemistry to clinic: Apelin and biased signalling in the cardiovascular system* - 102

Dr Anthony Davenport, University of Cambridge, UK

**Sponsored by** [CER](#) (image)

#### 09:30–10:25
**Morning tea with exhibitors**

**Clarendon Auditorium foyer, Level 2**

**Poster presentations:** Drug Disposition and Response, Clinical Pharmacology, Drug Discovery, Pharmacoepidemiology

**Sponsored by** [ACS Chemical Neuroscience](#) (image)

**SIG meeting: Toxicology**

**Room:** Clarendon Room A, Level 5

**SIG meeting: Education Forum**

**Room:** Clarendon Room A, Level 5

#### 10:30–12:30
**Symposium 1: Novel GPCR targets for the treatment of CVD**

**Room:** Clarendon Auditorium, Level 2

**Chairs:** Dr Lauren May; Dr Tamara Paravicini

**Orphan GPCRs in the development of cardiovascular disease** - 103

Dr Nicola Smith, Victor Chang Cardiac Research Institute

**Targeting protease-activated receptors for prevention of arterial thrombosis: Current and future approaches** - 104

Dr Justin Hamilton, Monash University

**Protecting the heart through opioid receptor activation** - 105

Dr Jason Peart, Griffith University

**Formyl Peptide Receptors - Novel GPCR targets for the treatment of cardiovascular diseases** - 106

Assoc Prof Rebecca Ritchie, Baker IDI Heart and Diabetes Institute

**The blood-brain barrier: Is it more of a barrier to CNS access in Alzheimer’s disease?** - 107

Dr J Joseph Nicolazzio, Monash University

**Prescribing considerations for people with dementia** - 108

Assoc Prof Sarah Hillmer, University of Sydney

**Drug use in dementia: Patterns and outcomes** - 109

Assoc Prof Simon Bell, Monash University; Dr Daniela Grijdic, University of Sydney

**Patterns of drug use among people with dementia: A Nordic example** - 110

Assoc Prof Kristina J onell, Karolinska Institutet and Stockholm University, Sweden

**Ability of older people with dementia or cognitive impairment to manage medicine regimes** - 111

Assoc Prof Susan Koch, Royal District Nursing Service

**Supported by** [MONASH University Centre for Medicine Use and Safety](#) (image)

#### 12:30–13:25
**Lunch with exhibitors**

**Clarendon Auditorium foyer, Level 2**

**Poster presentations:** Drug Disposition and Response, Clinical Pharmacology, Drug Discovery, Pharmacoepidemiology

**Sponsored by** [City of Melbourne](#) (image)

**SIG meeting: Urogenital and Gastrointestinal**

**Room:** Clarendon Room B, Level 5

#### 13:30–15:30
**Symposium 3: Education symposium: Micro to macro and back again**

**Room:** Clarendon Auditorium, Level 2

**Chair:** Dr Liz Davis

**Reflections on teaching complex concepts** - 112

Prof Arthur Christopoulos, Monash University

**Teaching prescribing to undergraduate medical students** - 113

Ms Anne Leversha, Monash University

**Unrecognisable transparency for quality and productivity and smarter education** - 114

Prof Hamish Coates, University of Melbourne

**Panel discussion**

**Sponsored by** [NAPE](#) (image)

**Symposium 4: Partners in crime: Regulation of cell signalling beyond GPCRs**

**Room:** Clarendon Room A, Level 5

**Chair:** Dr Michelle Halls

**The role of GPCR signalling via dual kinase receptor transactivation in cardiovascular disease** - 115

Prof Peter Little, RMIT University

**Angiotensin II-mediated EGFR transactivation: Identify new signalling mediators important for tissue remodelling in cardiovascular disease and cancer** - 116

Prof Walter Thomas, The University of Queensland

**Endosomal platforms for signalling pain** - 117

Prof Nigel Bunnett, Monash University

**Delineating the dynamics of mu-opioid receptor signalling and regulation** - 118

Dr Merrell Canals, Monash University

**Supported by** [PerkinElmer](#) (image)

#### 15:30–15:55
**Afternoon tea with exhibitors**

**Clarendon Auditorium foyer, Level 2**

**SIG meeting: Cardiovascular**

**Room:** Clarendon Room A, Level 5
**Oral presentations 1: Drug Disposition and Response/Pharmacogenomics/Pharmacoepidemiology**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:15</td>
<td>UDP-glucosyltransferase 8 (UGT8) galactosidates bile acids and modulates FXR signalling</td>
<td>Dr David Foster</td>
</tr>
<tr>
<td></td>
<td>- 123 Robyn Meech, Flinders University</td>
<td></td>
</tr>
<tr>
<td>16:15-16:30</td>
<td>Population pharmacokinetic modelling of colistin methanesulphonate and formed colistin</td>
<td>Prof Patrick Sexton</td>
</tr>
<tr>
<td></td>
<td>in patients receiving intermittent haemodialysis - 124 Comelia Landersdorfer, Monash</td>
<td></td>
</tr>
<tr>
<td></td>
<td>University</td>
<td></td>
</tr>
<tr>
<td>16:30-16:45</td>
<td>Extremes of body size in the dosing of high-dose methotrexate chemotherapy for non-Hodgkin</td>
<td>Dr David Foster</td>
</tr>
<tr>
<td></td>
<td>lymphoma - 125 Geeta Sandhu, The University of Queensland</td>
<td></td>
</tr>
<tr>
<td>16:45-17:00</td>
<td>Prostacyclin activates the IP-receptor to promote migratory behaviour in breast cancer cells</td>
<td>Assoc Prof Peter Molenaar</td>
</tr>
<tr>
<td></td>
<td>that over-express cyclooxygenase-2 - 126 Sarah Allison, The University of Sydney</td>
<td></td>
</tr>
<tr>
<td>17:00-17:15</td>
<td>Innate immune signalling genetics associated with cognitive dysfunction and adverse opioid</td>
<td>Dr Karen Gregory, Monash University</td>
</tr>
<tr>
<td></td>
<td>effects in cancer pain patients on transdermal fentanyl - 127 Daniel Barratt, University of Adelaide</td>
<td></td>
</tr>
<tr>
<td>17:15-17:30</td>
<td>A multistate model for the role of multiple medication use and Drug Burden Index in frailty</td>
<td>Dr Jane Carland, University of Sydney</td>
</tr>
<tr>
<td></td>
<td>state transitions and death: The CHAMP study - 128 Kris Jansen, Monash University</td>
<td></td>
</tr>
<tr>
<td>17:30-17:45</td>
<td>Prevalence of potential statin-drug interactions in frail and robust older inpatients - 129</td>
<td>Assoc Prof Simon Bell, Monash University</td>
</tr>
<tr>
<td></td>
<td>Michele Thai, The University of Sydney</td>
<td></td>
</tr>
<tr>
<td>17:45-18:00</td>
<td>Psychotropic drug utilisation in older people in New Zealand from 2005 to 2013 - 130</td>
<td>Assoc Prof Peter Molenaar</td>
</tr>
<tr>
<td></td>
<td>Henry Ndulue, University of Otago, New Zealand</td>
<td></td>
</tr>
</tbody>
</table>

**Oral presentations 2: Drug Discovery**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:15</td>
<td>Structure-activity analysis of biased agonism at the adenosine A&lt;sub&gt;2&lt;/sub&gt;e receptor - 131</td>
<td>Dr David Foster</td>
</tr>
<tr>
<td></td>
<td>Jo-Anne Balts, Monash University</td>
<td></td>
</tr>
<tr>
<td>16:15-16:30</td>
<td>Structure of the M&lt;sub&gt;2&lt;/sub&gt; muscarinic acetylcholine receptor and insights into its allosteric modulation - 132</td>
<td>Assoc Prof Peter Molenaar</td>
</tr>
<tr>
<td></td>
<td>David Thal, Monash University</td>
<td></td>
</tr>
<tr>
<td>16:30-16:45</td>
<td>Ryanodine receptors: A novel target for cigarette smoking-related lung disease - 131</td>
<td>Dr Karen Gregory, Monash University</td>
</tr>
<tr>
<td></td>
<td>Chantal Donovan, University of Melbourne</td>
<td></td>
</tr>
<tr>
<td>16:45-17:00</td>
<td>A novel single chain H2 relaxin analogue causes biased signalling at the Relaxin Family Peptide Receptor 1 - 134</td>
<td>Dr Karen Gregory, Monash University</td>
</tr>
<tr>
<td></td>
<td>Martina Kocan, Monash University</td>
<td></td>
</tr>
<tr>
<td>17:00-17:15</td>
<td>miR-126 regulation in a mouse model of laser-induced choroidal neovascularisation - 135</td>
<td>Dr Karen Gregory, Monash University</td>
</tr>
<tr>
<td></td>
<td>Amy Lee, University of Melbourne</td>
<td></td>
</tr>
<tr>
<td>17:15-17:30</td>
<td>The role of the extracellular vestibule in R2 adrenocortical and allosteric ligand interactions - 136</td>
<td>Dr Karen Gregory, Monash University</td>
</tr>
<tr>
<td></td>
<td>Erica Leonar, The University of New South Wales</td>
<td></td>
</tr>
<tr>
<td>17:30-17:45</td>
<td>Beta2-adrenoceptor signalling promotes invasion of human breast cancer cells - 137</td>
<td>Dr Karen Gregory, Monash University</td>
</tr>
<tr>
<td></td>
<td>Cindy Pon, Monash University</td>
<td></td>
</tr>
<tr>
<td>17:45-18:00</td>
<td>Novel positive allosteric modulators of the delta opioid receptor - 138</td>
<td>Dr Karen Gregory, Monash University</td>
</tr>
<tr>
<td></td>
<td>Holly Yeatman, Monash University</td>
<td></td>
</tr>
</tbody>
</table>

**Symposium 5: ASCEPT Denis Wade Johnson & Johnson New Investigators**

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00-16:15</td>
<td>Molecular insights into metabotropic glutamate receptor allosteric modulation - 119</td>
<td>Dr Karen Gregory, Monash University</td>
</tr>
<tr>
<td></td>
<td>Dr Karen Gregory, Monash University</td>
<td></td>
</tr>
<tr>
<td>16:15-16:30</td>
<td>Optimising medication use in people with dementia: Evidence and opportunities - 120</td>
<td>Assoc Prof Peter Molenaar</td>
</tr>
<tr>
<td></td>
<td>Dr Karen Gregory, Monash University</td>
<td></td>
</tr>
<tr>
<td>16:30-16:45</td>
<td>Novel inhibitors of glycine transporters - 121</td>
<td>Dr Jane Carland, University of Sydney</td>
</tr>
<tr>
<td></td>
<td>Dr Jane Carland, University of Sydney</td>
<td></td>
</tr>
<tr>
<td>16:45-17:00</td>
<td>Targeting synaptic adaptations in chronic pain - 122</td>
<td>Dr Wendy Imlach, University of Sydney</td>
</tr>
<tr>
<td></td>
<td>Dr Wendy Imlach, University of Sydney</td>
<td></td>
</tr>
</tbody>
</table>

---

**About CERA**

The Centre for Education and Research on Ageing (CERA) is a multidisciplinary Centre that aims to expand and share knowledge of human ageing, so that the health and quality of life of older people can be improved.

CERA is a faculty of the University of Sydney, Sydney Medical School and Concord Repatriation General Hospital, a teaching hospital within Sydney South West Area Health Service. CERA is located at Concord Repatriation General Hospital in the inner west of Sydney, Australia.

**CERA’s Research Programs**

Research at CERA is concerned with the ageing process, and the disorders and diseases that are most likely to cause disability and reduced quality of life in old age. Our Research Program is multidisciplinary, linking laboratory, clinical, epidemiological and health services research and is primarily funded by the National Health and Medical Research Council and the Australian Research Council.

**Supported by:**

[Ageing and Alzheimers Institute]
# Tuesday 9 December, 2014

## ASCEPT Plenary presentation

**Molecular Pharmacology of GPCRs (MPGPCR)**

**Opening plenary presentation**

### Tuesday 9 December, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30-10:30</td>
<td>Morning tea with exhibitors</td>
</tr>
<tr>
<td>10:30-12:30</td>
<td>Oral presentations 3: Clinical Pharmacology/Education</td>
</tr>
<tr>
<td>13:30-14:30</td>
<td>Lunch with exhibitors</td>
</tr>
<tr>
<td>14:30-16:30</td>
<td>Molecular Pharmacology of GPCRs (MPGPCR) Opening plenary presentation</td>
</tr>
</tbody>
</table>

### Room Details

- Clarendon Auditorium, Level 2
- Clarendon Auditorium foyer, Level 2
- Clarendon Room A, Level 5
- Clarendon Room B, Level 5

### Chair

- Assoc Prof Peter Molenaar

**From drug metabolism and Pharmacogenetics to diagnostics and drug discovery - 201**

- Prof Edith Sim, Kingston University and Department of Pharmacology, University of Oxford, UK

## SIG meetings:

### Drug Disposition and Response

- Room: Clarendon Room B, Level 5
- Chairs: Dr Angela Finch; Dr Brad Broughton

### Drug Discovery

- Room: Clarendon Room B, Level 5
- Chairs: Dr Nicole Jones; Dr Brad Broughton

### Pharmacoepidemiology

- Room: Clarendon Room A, Level 5

## Oral presentations 3:

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30-10:45</td>
<td>Trough concentrations of infliximab and adalimumab, and anti-drug antibodies, correlate with drug response in inflammatory bowel disease - 210</td>
</tr>
<tr>
<td></td>
<td>Murray Barclay, Christchurch Hospital, New Zealand</td>
</tr>
<tr>
<td>10:45-11:00</td>
<td>The ideal anticoagulant is a myth - 211</td>
</tr>
<tr>
<td></td>
<td>Stephen Duffull, University of Otago, New Zealand</td>
</tr>
<tr>
<td>11:00-11:15</td>
<td>Neprilysin inhibitors preserve renal function in heart failure - meta-analysis of randomised controlled trials - 212</td>
</tr>
<tr>
<td></td>
<td>Ingrid Hopper, Monash University</td>
</tr>
<tr>
<td>11:15-11:30</td>
<td>Insights into the pathophysiology of hyperuricaemia - 213</td>
</tr>
<tr>
<td></td>
<td>Dilkun Kanangara, St Vincent's Hospital</td>
</tr>
<tr>
<td>11:30-11:45</td>
<td>The influence of inamidine on disease progression in patients with gastro-intestinal stromal tumour (GIST) - 214</td>
</tr>
<tr>
<td></td>
<td>Shaun Kumar, St Vincent's Hospital</td>
</tr>
<tr>
<td>11:45-12:00</td>
<td>Piperacillin pharmacokinetics in intensive care unit patients with anuria and acute kidney injury receiving sustained low efficiency dialfiltration - 215</td>
</tr>
<tr>
<td></td>
<td>Mahipal Sinnolareddy, The Queen Elizabeth Hospital; University of South Australia</td>
</tr>
<tr>
<td>12:00-12:15</td>
<td>Using peer-assisted learning in an Honours program to enhance student engagement and performance - 216</td>
</tr>
<tr>
<td></td>
<td>Barbara Kemp-Harper, Monash University</td>
</tr>
<tr>
<td>12:15-12:30</td>
<td>Learning styles and blended learning strategies for teaching pharmacology - 217</td>
</tr>
<tr>
<td></td>
<td>Roslyn Rose Meyer, Griffith University</td>
</tr>
</tbody>
</table>

## Oral presentations 4:

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30-14:45</td>
<td>Antagonist actions at the N40D (A118G) polymorphism of the human µ opioid receptor in vitro - 219</td>
</tr>
<tr>
<td></td>
<td>Jonathan Javitch, Columbia University, USA</td>
</tr>
<tr>
<td>14:45-15:00</td>
<td>Clinical use of an aminoglycoside ward-based Therapeutic Drug Monitoring (TDM) service in a tertiary hospital - 220</td>
</tr>
<tr>
<td></td>
<td>Maneesha Dedigama, Flinders Medical Centre</td>
</tr>
<tr>
<td>15:00-15:15</td>
<td>Has the availability of new oral anticoagulants (NOACs) changed the way older inpatients are selected for oral anticoagulation? - 221</td>
</tr>
<tr>
<td></td>
<td>Nicholas Farinola, Royal Adelaide Hospital</td>
</tr>
</tbody>
</table>
The British Journal of Pharmacology is a broad-based journal giving leading international coverage of all aspects of experimental pharmacology. It publishes high quality original research and authoritative reviews. Each year a range of themed issues are published and a must-read issue, the Concise Guide to PHARMACOLOGY, is published biennially.

s¬4HE¬LEADING¬GENERAL¬PHARMACOLOGY¬RESEARCH¬JOURNAL
s¬¬)MPACT¬&ACTOR¬

s¬2ECENT¬THEMED¬CONTENT¬INCLUDES¬¬
Animal Models In Psychiatry Research, Nanomedicine AND Molecular Pharmacology of GPCRs

s¬#ONCISE¬’UIDE¬TO¬0(!2-!#/,/'9¬¬n¬
AVAILABLE¬FREE
s¬&REE¬APP¬AVAILABLE¬FOR¬DOWNLOAD¬VIA¬I4UNES

Chosen Publisher of BPS

Editor-in-Chief: Professor Ian McGrath

The British Journal of Pharmacology is a broad-based journal giving leading international coverage of all aspects of experimental pharmacology. It publishes high quality original research and authoritative reviews. Each year a range of themed issues are published and a must-read issue, the Concise Guide to PHARMACOLOGY, is published biennially.

- The leading general pharmacology research journal
- 2013 Impact Factor: 4.990
- Recent themed content includes: Animal Models In Psychiatry Research, Nanomedicine and Molecular Pharmacology of GPCRs
- Concise Guide to PHARMACOLOGY 2013/2014 – available free
- Free app available for download via iTunes

Visit the journal and sign up for content alerts: www.brjpharmacol.org
**Wednesday 10 December, 2014**

**08:00–17:00**

**Registration desk open**

**08:30–09:30**

**Plenary presentation: ASCEPT Lecture**

Clarendon Auditorium

**Chair:** Assoc Prof Peter Molenaar

Controlling signalling of class B G protein-coupled receptors - 301

Prof Patrick Sexton, Monash Institute of Pharmaceutical Sciences, Monash University

**09:30–10:25**

**Morning tea with exhibitors**

Clarendon Auditorium foyer, Level 2

Poster presentations: MPGPCR

ASCEPT student poster prize session

Sponsored by

**10:30–12:30**

**Oral presentations 6: ASCEPT Garth McQueen Oral Prize**

Room: Clarendon Room B, Level 5

**Chair:** Dr Nicole Jones

**10:30-10:45**

AT1 receptor/Insulin Regulated Aminopeptidase (IRAP): A target for protection in cardiovascular disease - 311

Huey Wen Lee, Monash University

**10:45-11:00**

Biased agonism in the 4th dimension: The contribution of binding kinetics to the bias profile of antipsychotic drugs at the dopamine D2 receptor - 312

Carmen Klein Herenbrink, Monash University

**11:00-11:15**

A switched on receptor - a role for adenosine A2A receptor constitutive activity in cancer cell proliferation - 313

Elizabeth Vecchio, Monash University

**11:15-11:30**

The effect of ageing on isoniazid pharmacokinetics and hepatotoxicity in Fischer 344 rats - 314

J ohn Mach, Kolling Institute of Medical Research

**11:30-11:45**

Bladder sensory nerve activity is enhanced by the cytotoxic drugs cyclophosphamide and ifosfamide - 315

Kylie Mills, Bond University

**11:45-12:00**

Serelaxin signalling in human primary vascular cells: G-proteins and their location determines the shape of the concentration-response relationship - 316

Mohsin Sarwar, Monash University

**12:00-12:15**

Healthcare practitioners’ perspectives on prescribing and deprescribing anticholinergic and sedative medications in older adults - 317

Lisa Kouladjian, University of Sydney

**12:15-12:30**

Quantification of the forgiveness of drugs to imperfect adherence - 318

Piyanan Assawasuwannakul, University of Otago, New Zealand

**12:30–13:25**

**Lunch with exhibitors**

Clarendon Auditorium foyer, Level 2

Poster presentations: MPGPCR

ASCEPT student poster prize session

Sponsored by

**12:30–13:25**

**SIG meeting: Neuropharmacology**

Room: Clarendon Room B, Level 5

**SIG meeting: Clinical Pharmacology**

Room: Clarendon Room A, Level 5

**13:30–14:30**

**SIG meeting: Cardiac safety vs efficacy: Focus on heart failure**

Room: Clarendon Room A, Level 5

Chair: Dr Felicity Grezmski; Assoc Prof Rebecca Ritchie

**14:45-15:30**

**SIG meeting:**

Applying pharmacology principles to target selection and target safety assessment - 305

Dr Gianlucififfe, Pfizer Inc, USA

Development of new in silico methods for assessing the pro-arrhythmic risk of drugs - 306

Prof Jamie Vandenberg, Victor Chang Cardiac Research Institute

Development of cardiac failure models as translational pharmacology models for diabetic cardiomyopathy and diastolic heart failure - 307

Assoc Prof Rebecca Ritchie, Baker IDI Heart and Diabetes Institute

**In silico prediction of Ames mutagenicity based on molecular descriptors - 308**

Dr Slade Matthews, The University of Sydney

**Augmented Caveolin 3 in cardiomyocytes limits age-related ischemic intolerance: Scaffolding hypothesis of aging - 309**

Dr Melissa Reichert, The University of Queensland

**Endogenous Annexin-A1 (ANX-A1) is cardioprotective against myocardial infarction(MI) in mice in vivo - 310**

Sibhban Finlayson, Baker IDI Heart and Diabetes Institute

Panel discussion

Sponsored by

**15:30–16:00**

**SIG meeting: Inflammation/respiratory**

Room: Clarendon Room B, Level 5

**16:30–17:30**

**SIG meeting:**

**16:30-17:30**

**Panel discussion**

**17:30–18:30**

**Panel discussion**

**18:00–19:00**

**Panel discussion**
More than 700,000 Australians take one or more Servier products every day.

**Research Platforms in Drug Discovery**

Consider engaging our network of experts for your drug discovery research needs.

**Centre for Drug Candidate Optimisation (CDCO)**

The CDCO is a collaborative research centre that provides ADME drug candidate optimisation expertise to support drug discovery and development. [https://platforms.monash.edu/cdco](https://platforms.monash.edu/cdco)

**Australian Translational Medicinal Chemistry Facility (ATMCF)**

By working to a suitably defined target product profile (TPP) that addresses an unmet medical need, the complimentary capabilities of the partner and the ATMCF and its other ancillary partners will be combined to achieve a fully integrated drug discovery platform. Contact jonathan.baell@monash.edu

**MONASH University**

Institute of Pharmaceutical Sciences

---

**Drug Discovery Biology**

Accelerating discovery from concept to clinic.

Join Australia’s number-one and a world’s top-ten pharmacology and pharmacy program for an exciting and successful PhD!

“DDB offers state-of-the-art facilities and great travel opportunities for students who would like to experience cutting edge science, both in Australia and with collaborators overseas”

Kathy Sengmany, 1st year PhD student.

[monash.edu/pharm/research/areas/drug-discovery](monash.edu/pharm/research/areas/drug-discovery)

facebook.com/MIPSDDB

---

**SCHOOL OF BIOMEDICAL SCIENCES**

Research Opportunities

The School is a strong supporter of research fellows and scientists. We offer a highly collaborative and collegial environment for both burgeoning researchers and established teams. Our newly renovated labs and strong cohort of research students provide a unique opportunity to conduct state-of-the-art biomedical research. We are situated in the heart of the biomedical precinct on the beautiful St Lucia main campus.

More information on the School of Biomedical Sciences is available online [www.uq.edu.au/sbms](www.uq.edu.au/sbms) or by contacting the Head of School, Professor Wally Thomas.

T 07 3365 2905
E w.thomas@uq.edu.au

www.uq.edu.au/sbms

---

---
### JOINT SCIENTIFIC MEETING 2015
#### ASCEPT - MPSGCR

**Hotel Grand Chancellor Hobart**

29 November - 2 December 2015

**Sponsored by**

MONASH University
Institute of Pharmaceutical Sciences

---

### Oral presentations 7: Neuro-Behavioural/Toxicology

**Room: Clarendon Room B, Level 5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-15:30</td>
<td><strong>Auditing adulterants: Toxicological assessment of herbal medicines sold in Australia during 2014</strong> - 331</td>
<td>Dr Mark Hutchinson</td>
</tr>
<tr>
<td>14:15-15:30</td>
<td><strong>Muscarinic acetylcholine M4 receptor regulation of psychosis-like behaviours induced by a dopamine D1 receptor-selective agonist in mice</strong> - 334</td>
<td>Amy Nae-Yng Chen, Monash University</td>
</tr>
</tbody>
</table>

### Oral presentations 8: Cardiovascular

**Room: Clarendon Auditorium, Level 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-15:30</td>
<td><strong>Resveratrol and SIRT1 do not protect against paracetamol toxicity</strong> - 333</td>
<td>Alice Kane, Kolling Institute of Medical Research</td>
</tr>
<tr>
<td>14:45-15:00</td>
<td><strong>Muscarinic acetylcholine M4 receptor regulation of psychosis-like behaviours induced by a dopamine D1 receptor-selective agonist in mice</strong> - 334</td>
<td>Amy Nae-Yng Chen, Monash University</td>
</tr>
</tbody>
</table>

### MPGPCR Symposium 3: GPCRs in pain and inflammation

**Room: Clarendon Room A, Level 5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30-14:45</td>
<td><strong>Protease-activated-receptor signaling in the airway: The good, the bad and the proinflammatory</strong> - 327</td>
<td>Prof Kathryn De'ea, UC Riverside</td>
</tr>
<tr>
<td>14:30-15:00</td>
<td><strong>Role for endothelial cell mineralocorticoid receptors in aldosterone-induced oxidative stress and inflammation in the brain</strong> - 320</td>
<td>Sophocles ChriSSobolis, Monash University</td>
</tr>
<tr>
<td>14:15-17:15</td>
<td><strong>Muscarinic acetylcholine M4 receptor regulation of psychosis-like behaviours induced by a dopamine D1 receptor-selective agonist in mice</strong> - 334</td>
<td>Amy Nae-Yng Chen, Monash University</td>
</tr>
</tbody>
</table>

### Room: Clarendon Auditorium foyer, Level 2

**13:30-17:15**

- **Exploring the synthetic cannabinome: Actions of PB-22 and 5F-PB-22** - 337
  - Dr Jordan Stuart, Macquarie University

- **PDE3 and PDE4 reduce the occurrence of β2- and β1-adrenoceptor mediated spontaneous contractions in isolated human right ventricular trabeculae from patients with terminal heart failure** - 324
  - Peter Molenaar, Queensland University of Technology

### Room: Clarendon Room A, Level 5

**13:30-15:15**

- **Cardiac dysfunction and ischaemic intolerance in murine type II diabetes mellitus is reversed by sustained ligand-activated preconditioning** - 326
  - Louise See Hoe, Griffith University

### Room: Clarendon Room B, Level 5

**13:30-15:15**

- **Muscarinic acetylcholine M4 receptor regulation of psychosis-like behaviours induced by a dopamine D1 receptor-selective agonist in mice** - 334
  - Amy Nae-Yng Chen, Monash University

### Room: Clarendon Auditorium, Level 2

**13:30-15:15**

- **Phosphoinositide 3-kinase p110α (PI3K) signalling** - 322
  - Miles De Blasio, Baker IDI Heart and Diabetes Institute

### Room: Clarendon Room B, Level 5

**13:30-15:15**

- **PDE3 and PDE4 reduce the occurrence of β2- and β1-adrenoceptor mediated spontaneous contractions in isolated human right ventricular trabeculae from patients with terminal heart failure** - 324
  - Peter Molenaar, Queensland University of Technology
The National Alliance for Pharmacy Education is a partnership between four leading universities that aims to provide leadership in pharmacy education and advancement of the profession.

- Postgraduate education in clinical pharmacy and pharmacy practice
- Leadership in pharmacy education
- Promoting excellence beyond competence
- Collaborating to advance the practice of pharmacy

Education pathway

Pharmacy degree

Intern Training Program

Postgraduate degree

- Clinical pharmacy
- Pharmacy practice

Graduation Registration Advanced Practice

The British Pharmacological Society has, at its heart, the development and promotion of pharmacology and of those who are training and working in the field. With over 3,500 members from over 60 countries around the world, we are a truly international organization. We cover the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects and support our members at work in academia, industry and the health service.

Benefits:
- Free or discounted rates at our scientific meetings
- Keeping up-to-date with developments in pharmacology by networking with the Society’s >3,500 members worldwide: at special networking events hosted by the Society or online at www.bps.ac.uk/Home/Find-a-member
- Free access to the British Journal of Pharmacology and British Journal of Clinical Pharmacology including articles accessed through the iPhone/iPad app for each journal
- Becoming eligible to apply for bursaries to attend scientific meetings
- BPS aims to give financial support to all eligible applicants and give out £50,000 in travel awards each year

Follow us:
- Facebook
- Twitter
- YouTube
- LinkedIn

Join us today!

The British Pharmacological Society has, at its heart, the development and promotion of pharmacology and of those who are training and working in the field. With over 3,500 members from over 60 countries around the world, we are a truly international organization. We cover the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects and support our members at work in academia, industry and the health service.

Membership types

Full Member
For Pharmacologists and Clinical Pharmacologists.
Standard Tariff - £105

Associate Member
Open to individuals having a professional interest in pharmacology or a closely related subject who do not have the necessary qualifications to become Members.
Standard Tariff - £70

Postgraduate Member
Open to individuals studying for higher degrees in pharmacology or a closely related subject. Also open to clinicians in training who have a specific interest or intend to follow a career in clinical pharmacology.
Standard Tariff - £20

Undergraduate Member
Open to individuals studying for degrees in pharmacology and other subjects whose courses include a substantial pharmacology component. Also open to medical students at any stage of training.
Standard Tariff - Free

Follow us:
- Facebook
- Twitter
- YouTube
- LinkedIn

Contact
Paul Tizard
0HPEHUVKLS	$ZDUGV2IÀFHU
7HO
(PDLOPHPEHUVKLS#ESVDFXN
Paul Tizard
0HPEHUVKLS	$ZDUGV2IÀFHU
7HO
(PDLOPHPEHUVKLS#ESVDFXN
www.bps.ac.uk/members

Becoming eligible to apply for bursaries to attend scientific meetings.
BPS aims to give financial support to all eligible applicants and give out £50,000 in travel awards each year

Follow us:
- Facebook
- Twitter
- YouTube
- LinkedIn

www.bps.ac.uk/members

The British Pharmacological Society has, at its heart, the development and promotion of pharmacology and of those who are training and working in the field. With over 3,500 members from over 60 countries around the world, we are a truly international organization. We cover the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects and support our members at work in academia, industry and the health service.

Membership types

Full Member
For Pharmacologists and Clinical Pharmacologists.
Standard Tariff - £105

Associate Member
Open to individuals having a professional interest in pharmacology or a closely related subject who do not have the necessary qualifications to become Members.
Standard Tariff - £70

Postgraduate Member
Open to individuals studying for higher degrees in pharmacology or a closely related subject. Also open to clinicians in training who have a specific interest or intend to follow a career in clinical pharmacology.
Standard Tariff - £20

Undergraduate Member
Open to individuals studying for degrees in pharmacology and other subjects whose courses include a substantial pharmacology component. Also open to medical students at any stage of training.
Standard Tariff - Free

Follow us:
- Facebook
- Twitter
- YouTube
- LinkedIn

Contact
Paul Tizard
0HPEHUVKLS	$ZDUGV2IÀFHU
7HO
(PDLOPHPEHUVKLS#ESVDFXN
Paul Tizard
0HPEHUVKLS	$ZDUGV2IÀFHU
7HO
(PDLOPHPEHUVKLS#ESVDFXN
www.bps.ac.uk/members

Becoming eligible to apply for bursaries to attend scientific meetings.
BPS aims to give financial support to all eligible applicants and give out £50,000 in travel awards each year

Follow us:
- Facebook
- Twitter
- YouTube
- LinkedIn

www.bps.ac.uk/members

The National Alliance for Pharmacy Education is a partnership between four leading universities that aims to provide leadership in pharmacy education and advancement of the profession.

- Postgraduate education in clinical pharmacy and pharmacy practice
- Leadership in pharmacy education
- Promoting excellence beyond competence
- Collaborating to advance the practice of pharmacy

Our priority research areas include:

- Infection and immunity
- Cardiovascular disease
- Cancer
- Development and stem cells
- Neuroscience
- Metabolic disease

To engage with our research community:
tbps@monash.edu
www.med.monash.edu/biomed-psych

Join us today!
### Thursday 11 December, 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00-17:00</td>
<td>Registration desk open</td>
<td></td>
</tr>
<tr>
<td>08:30–09:30</td>
<td>MPGPCR Symposium 5: MPGPCR BPS Student Oral Prize</td>
<td>Chair: Dr Karen Gregory</td>
</tr>
<tr>
<td>08:30-08:45</td>
<td>GPR37L1: An orphan G protein-coupled receptor with constitutive activity modulated by novel metalloprotease-mediated N-terminal cleavage - 401</td>
<td>James Coleman, Victor Chang Cardiac Research Institute</td>
</tr>
<tr>
<td>08:45-09:00</td>
<td>Identification of the mechanisms which govern allosterism at the dopamine D2 receptor - 402</td>
<td>Christopher Draper-J Joyce, Monash University</td>
</tr>
<tr>
<td>09:00-09:15</td>
<td>Structural basis for G protein-mediated high-affinity agonist binding to GPCRs - 403</td>
<td>Jacob Mahoney, University of Michigan, USA</td>
</tr>
<tr>
<td>09:15-09:30</td>
<td>Allosteric modulation of the mu opioid receptor - 404</td>
<td>Kathryn Livingston, University of Michigan, USA</td>
</tr>
<tr>
<td>09:30–10:10</td>
<td>MPGPCR Symposium 6: Structure-function of GPCRs</td>
<td>Chair: Prof Patrick Sexton</td>
</tr>
<tr>
<td>09:30–10:10</td>
<td>Allostery in GPCR biology: Form, function and potential therapeutics - 405</td>
<td>Prof Roger Sunahara, University of Michigan, USA</td>
</tr>
<tr>
<td>10:10–10:35</td>
<td>Morning tea with exhibitors</td>
<td></td>
</tr>
<tr>
<td>10:40–12:40</td>
<td>MPGPCR Symposium 6: Structure-function of GPCRs (continued)</td>
<td></td>
</tr>
<tr>
<td>10:40-11:20</td>
<td>Conformational dynamics in the allosteric regulation of B2-adrenergic receptor signaling - 406</td>
<td>Prof R. Scott Prosser, University of Toronto, Canada</td>
</tr>
<tr>
<td>11:20-12:00</td>
<td>Exploring GPCR ligand interactions through structural and biophysical studies - 407</td>
<td>Dr Robert Cooke, Heptares Therapeutics, UK</td>
</tr>
<tr>
<td>12:00-12:40</td>
<td>Crystal structure of rhodopsin bound to arrestin determined by femtosecond X-ray laser - 408</td>
<td>Prof Eric Xu, Institute of Materia Medica, Shanghai</td>
</tr>
<tr>
<td>12:40–13:25</td>
<td>Lunch with exhibitors</td>
<td></td>
</tr>
<tr>
<td>13:30–15:30</td>
<td>MPGPCR Symposium 7: Signalling in space and time</td>
<td>Chair: Dr Rob Lane</td>
</tr>
<tr>
<td>13:30-14:10</td>
<td>GPCR-G protein signaling from endosomes - 409</td>
<td>Prof Mark von Zastrow, The University of California, San Francisco</td>
</tr>
<tr>
<td>14:10-14:50</td>
<td>Receptor localisation shapes the spatiotemporal dynamics of GPCR signalling - 410</td>
<td>Dr Michelle Halls, Monash University</td>
</tr>
<tr>
<td>14:50-15:30</td>
<td>From biochemistry to molecular imaging of GPCRs - 411</td>
<td>Prof Martin Lohse, University of Wurzburg, German</td>
</tr>
<tr>
<td>15:30–15:55</td>
<td>Afternoon tea with exhibitors</td>
<td></td>
</tr>
<tr>
<td>16:00–18:00</td>
<td>MPGPCR Symposium 8: Chemical Biology and Mechanistic Pharmacology</td>
<td>Chair: Prof Arthur Christopoulos</td>
</tr>
<tr>
<td>16:00-16:40</td>
<td>A new approach to treat ischaemic heart disease: Adenosine receptor biased agonism - 412</td>
<td>Dr Lauren May, Monash University</td>
</tr>
<tr>
<td>16:40-17:20</td>
<td>DualstERIC GPCR modulators with engineered efficacy to fine-tune muscarinic receptor signaling - 413</td>
<td>Prof Klaus Mohr, University of Bonn, Germany</td>
</tr>
<tr>
<td>17:20-18:00</td>
<td>Observed drug-receptor association rates are strongly influenced by membrane affinity: The importance of establishing micro PK/PD relationships - 414</td>
<td>Prof Steven Charlton, The University of Nottingham, UK</td>
</tr>
<tr>
<td>18:00–18:30</td>
<td>MPGPCR Awards and close</td>
<td>Chair: Dr Chris Langmead</td>
</tr>
</tbody>
</table>
Thank you to our sponsors

### Major sponsor

![cera logo](image)

**Centre for Education & Research on Ageing**

### Key sponsors

<table>
<thead>
<tr>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>City of Melbourne</td>
</tr>
<tr>
<td>NAPE</td>
</tr>
<tr>
<td>Monash University</td>
</tr>
<tr>
<td>UCB</td>
</tr>
<tr>
<td>BJP</td>
</tr>
<tr>
<td>Servier</td>
</tr>
<tr>
<td>Monash University Institute of Pharmaceutical Sciences</td>
</tr>
<tr>
<td>BPS British Pharmacological Society</td>
</tr>
<tr>
<td>Drug Discovery Biology</td>
</tr>
<tr>
<td>Merck</td>
</tr>
</tbody>
</table>

### Supporters

<table>
<thead>
<tr>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACS Chemical Neuroscience</td>
</tr>
<tr>
<td>Invion</td>
</tr>
<tr>
<td>DiscoverRx</td>
</tr>
<tr>
<td>Compounds Australia</td>
</tr>
<tr>
<td>The University of Sydney</td>
</tr>
<tr>
<td>Health Innovations Research Institute</td>
</tr>
<tr>
<td>BMG Labtech</td>
</tr>
<tr>
<td>ProImagen</td>
</tr>
<tr>
<td>Anatrace</td>
</tr>
<tr>
<td>Pfizer</td>
</tr>
<tr>
<td>Flinders University</td>
</tr>
<tr>
<td>Pharmacology &amp; Therapeutics</td>
</tr>
<tr>
<td>PerkinElmer For the Better</td>
</tr>
</tbody>
</table>

### Exhibitors

<table>
<thead>
<tr>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sapphire Bioscience</td>
</tr>
<tr>
<td>Eppendorf</td>
</tr>
<tr>
<td>AdInstruments</td>
</tr>
<tr>
<td>Bio-Strategy</td>
</tr>
<tr>
<td>GE</td>
</tr>
<tr>
<td>Oxford Optonix</td>
</tr>
<tr>
<td>GeneWorks</td>
</tr>
<tr>
<td>World Courier</td>
</tr>
<tr>
<td>PerkinElmer For the Better</td>
</tr>
<tr>
<td>BMG Labtech</td>
</tr>
</tbody>
</table>

### In kind support

<table>
<thead>
<tr>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapeutic Guidelines</td>
</tr>
</tbody>
</table>

---
ASPET is a nonprofit scientific society founded in 1908 devoted to advancing pharmacology and experimental therapeutics through scientific meetings, publications, education, and advocacy efforts. ASPET provides its members with the tools and resources to promote their research, advance their careers, and build lasting relationships with fellow scientists.

ASPET members work in a variety of different fields and include pharmacologists, chemical biologists, neuroscientists, toxicologists, pharmacists, cardiovascular scientists, and many more.

Though very diverse, our members have a common bond through their membership in ASPET. Our members’ research efforts help develop new medicines and therapeutic agents to fight existing and emerging diseases.

Apply for membership at www.aspet.org.

For more info contact: membership@aspet.org | (301) 634-7060 | www.aspet.org